I'm sorry that you're going through this. It's what we all worry about happening during treatment. Your husband's case is the first time I've heard about someone with BRAF on this board and the other board that I'm on and that's why I think that Genomic Tumor Testing should be done on all patients when there's a tumor biopsy available as it may change treatment plans and urgency.
Regarding CTCA - I would pick a top cancer center hospital over a for-profit for a second opinion, particularly when my life is at stake. And that's what I did by getting second opinions at Dana Farber and Brigham and Womens. The recommendation to get second opinions at top hospitals is a common one on this board.
Top cancer hospitals:
MD Anderson - Houston
Memorial Sloan Kettering - NYC
Mayo Clinic - Rochester, MN
Dana Farber Cancer Institute/Brigham and Womens - Boston, MA
University of Washington Medical Center - Seattle
John Hopkins - Baltimore, MD
Cleveland Clinic - Cleveland, OH
Penn Presbyterian - Philadelphia, PA
Moffitt Cancer Center - Tampa, FL
UCSF Medical Center - San Francisco, CA
Stanford Hospital - Stanford, CA
Mass General Hospital - Boston, MA
06/23/17: ER rectal bleeding; Colonoscopy+Biopsy
07/13/17: Stage 3B rectal cancer. T3, N1b, M0. 5.2 x 4.5 x 4.3 cm. Lymphs: 6 x 4 mm, 8 x 6 mm, 5 x 5 mm.
Xeloda 3,400 mg/day + radiation 07/31 - 09/08.
CEA 2.7; halfway through treatment: 1.9; after treatment: 1.8.
MSS, KRAS G12D
10/06/17: 2.7 x 2.2 x 1.6 cm (-90%). Lymphs: 3 x 3 mm (-62.5%), 4 x 3 mm (-75%), 5 x 3 mm (-40%). 5.1 CM from AV.
Surgery: 10/30/17 LAR, Temp Ileostomy